Adolescents and young adults with ALL benefit from paediatric protocols

Results from a large, prospective clinical trial add to mounting evidence that adolescent and young adult patients, aged 16 to 39 with acute lymphoblastic leukaemia (ALL), tend to fare better when treated with high-intensity paediatric protocols than previous patients who were treated with standard adult regimens. Read more here.